Prostate Cancer Diagnostics Market Driven by Growing Geriatric Demographic in Emerging Countries

Published On : 28 Jun 2017

QYResearchReports.com announces the addition of a new report on the global prostate cancer diagnostics market. The report presents a thorough review of the historical growth trajectory exhibited by the prostate cancer diagnostics market, comprehensive latest figures illustrating each corner of the growing market, and reliable forecasts regarding the global prostate cancer diagnostics market’s valuation in the coming years. The report is titled ‘Global Prostate Cancer Diagnostics Market Research Report 2017.’

According to the report, the global prostate cancer diagnostics market was valued at around US$11 bn in 2016. The market has exhibited a healthy growth rate in the ongoing decade due to the steady rise in demand and gradual discovery of new unaddressed patient demographics. 

The global prostate cancer diagnostics market is segmented by product type into imaging, biopsy, tumor biomarker tests, and others. A review of the historical figures and present status of each segment is given in the report, providing readers with a granular understanding of the product segmentation of the global prostate cancer diagnostics market. Similar attention is paid to the age segmentation of the global prostate cancer diagnostics market, wherein the report segments the market into 55-75, below 55, and above 75. The current figures of each age segment of the global prostate cancer diagnostics market are also provided. The report also provides forecasts till 2022 for each segment of the global prostate cancer diagnostics market.

Click to get more details with TOC in a PDF Format: http://www.qyresearchreports.com/sample/sample.php?rep_id=1054514&type=E

As prostate cancer is a primarily age-related condition, the global prostate cancer diagnostics market is likely to benefit significantly from the steady expansion of the geriatric demographic across the world. Improvement in the standard of healthcare has come naturally in developed countries, whereas developing economies with rapidly growing healthcare sectors have followed suit in recent years. The growing disposable income of the geriatric demographic in developing countries has helped drive growth of the prostate cancer diagnostics market and is likely to remain a key driver for the market in the coming years. The steady incorporation of technological advances in the healthcare sector in developed countries has helped the prostate cancer diagnostics market and is likely to be an important driver for the market in the coming years.

The report looks at the prostate cancer diagnostics market’s performance in North America, Europe, Japan, and Rest of Asia Pacific. These three regions contain some of the world’s largest geriatric demographics and thus are the key regions for the global prostate cancer diagnostics market. The prostate cancer diagnostics market is likely to exhibit steady growth in Asia Pacific countries such as China and India, in addition to Japan, in the coming years, due to the growing private investment in healthcare. 

The competitive dynamics of the global prostate cancer diagnostics market are also examined in the report, which profiles the key players operating in the prostate cancer diagnostics market in order to understand the competitive workings of the market. Leading companies examined in the report include Abbott, DiaSorin, Genomic Health, Roche, Siemens Healthcare, Myriad Genetics, MDx Health, OPKO, Ambry Genetics, bioMeriux, and Beckman Coulter. 
 

Top Trending Reports :

Back To Top